Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.

Hsiang-Fong Kao,Bin-Chi Liao,Yen-Lin Huang,Huai-Cheng Huang,Chun-Nan Chen,Tseng-Cheng Chen,Yuan-Jing Hong,Ching-Yi Chan,Ruey-Long Hong

Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.

2021

Hsiang-Fong Kao
Bin-Chi Liao
Yen-Lin Huang
Huai-Cheng Huang
Chun-Nan Chen
Tseng-Cheng Chen
Yuan-Jing Hong
Ching-Yi Chan
Ruey-Long Hong

6024Background: Epidermal growth factor receptor (EGFR) pathway inhibition may synergize with anti-PD1 activity by inhibiting macrophage function, increasing antigen presentation, and augmenting T ...

Keywords:

Alpha (ethology)
Epidermal growth factor receptor
Medicine
Pembrolizumab
Phases of clinical research
Antigen presentation
Cancer research
Afatinib
macrophage
Head and neck squamous-cell carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations